IntrOductIOn
18Fluorine -fluoro-2-deoxyglucose Positron Emission Tomography/ computed tomography (18F-FDG-PET/CT) is an important functional imaging modality in assessing high-risk thymoma and thymic carcinomas. Tumours of the thymus are uncommon and are usually considered as being indolent, although this is often true of thymomas; thymic adenocarcinoma and thymic neuroendocrine cancer can be aggressive and have a poor prognosis. Physiologic uptake of FDG is seen in the thymus in 28% of normal people aged less than 40 yrs, with the incidence dependent on the age of the patient, being identified in up to 73% of children under 13 y, decreasing up to 8% of people in their fourth decade [1] . Our primary objective was to assess the usefulness of 18F-FDG-PET, if FDG uptake can predict advanced thymoma, distinguish thymoma from thymic cancer and if 68Ga-DOTATATE-PET was useful in thymic carcinoma with neuroendocrine differentiation (NED).
MAterIAls And MethOds
We reviewed 18F-FDG-PET/CT scans of 12 consecutive newly diagnosed patients with thymic epithelial malignancy from January 2011 to May 2013 and documented focal FDG activity using SUV max. All patients fasted for at least 4 hr before undergoing 18F-FDG PET examination. The patients received an intravenous injection of 3.7-4.0 MBq/kg of 18F-FDG. Image acquisition was performed after 60 minutes using a PET-CT scanner (Biograph 6; Siemens Medical Solutions, Erlangen, Germany). Three-dimensional 
results
Of the 12 patients, nine were diagnosed to have thymoma, one thymic cyst, one thymic carcinoma and 1 thymic carcinoma with NED. Age ranged from 24-60 yrs; eight were males and four females.
The SUV max measured were as follows:
Low risk type thymoma 3-5
Type B3 thymoma 7.35
Thymic carcinoma 20.45
Thymic cyst was not 18F-FDG avid.
In NED 68Ga-DOTATATE imaging identified additional lesions and hence was superior to 18F-FDG PET/CT. dIscussIOn 18F-FDG-PET/CT in the diagnosis of mediastinal masses is not a routine investigation but is of significance in assessing high-risk thymoma and thymic carcinomas. CT and MRI are exceptional modalities for localization of mediastinal masses but has limited role in assessment of the aggressiveness of masses, identify viable tumour in residual masses after chemotherapy or radiotherapy.
Inoue and Luzzi et al., [2, 3] reported that SUVmax of low-risk thymomas containing types A, AB and B1 tumours was significantly lower than those of high-risk thymic tumours consisting of types B2 & B3 thymomas and thymic carcinomas. So much so that Luzzi et al., [3] suggested that 'any anterior mediastinal mass whose SUVmax is >5 not be resected without biopsy because of the possibility that it may be more aggressive than thymoma or even a nonsurgical disease such as lymphoma'. In our case series we found that patient with B3 had a higher SUVmax. Consistent with previous reports [4] [5] [6] [7] [8] , our study found higher FDG uptake in thymic carcinoma than in thymoma although there were no significant differences in uptake among high and low risk groups of thymoma. Sharma et al., [9] studied the role of 18F-FDG PET/ CT in thymic carcinoma diagnosis and reported that SUVmax of >/=7 in the presence of lobulated masses with areas of necrosis and calcification, encasement of mediastinal structures, pleural thickening, mediastinal lymphadenopathy and distant metastases was suggestive of thymic carcinoma.
Thymomas and thymic carcinomas are diverse with respect to oncological behaviour. Surgical resection is the main modality of treatment for thymomas and multidisciplinary treatment with induction chemotherapy is recommended for patients with Stage III disease with great vessel invasion or Stage IV disease [10, 11] . Thymic carcinomas are much more aggressive tumours, and the incidence of lymph node and distant metastasis is higher than that observed in thymomas.18F-FDG PET/CT is useful in the follow up and to assess response to therapy [Table/ Fig-1 ] of patients diagnosed with thymic tumours. 68Ga-DOTATATE-PET/CT is a valuable imaging modality in the diagnosis of neuroendocrine tumours. One patient with thymic carcinoma and NED underwent this imaging modality [Table/ Fig-2a -c] and additional lesions were picked up in comparison to FDG PET, thus indicating a useful role in NED. In 68Ga-DOTATATE avid tumours peptide receptor radiotherapy (PRRT) with 177Lutetium can be considered as the therapeutic option [12] . 18F-FDG PET imaging plays an important role in monitoring treatment response and predicting survival in advanced thymic epithelial tumours as shown by Thomas et al., [13] in a prospective study of 56 patients with Masaoka stage III and IV, metabolic responders had significantly longer progression-free survival of 11.5 vs 4.6 months suggesting that an early metabolic response closely correlates with therapy outcome.
cOnclusIOn
PET/CT is a valuable diagnostic tool in evaluation of thymic tumours, in initial workup, to assess treatment response and for prognostication. 68Ga-DOTATATE-PET/CT is valuable in assessing neuroendocrine thymic tumours and to plan for therapy with 177Lutetium-DOTATATE if positive. Focal FDG uptake cannot predict advanced thymoma but is helpful in distinguishing thymoma from thymic carcinoma. 
